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Abstract 
 
Germline mutations in BRCA1 and BRCA2 account for the vast majority of familial breast and 
ovarian cancer cases. Over the past 20 years, there has been considerable progress in our 
understanding of the biological functions of BRCA proteins, which has led to the development of new 
therapeutic approaches that target tumors with loss-of-function mutations in BRCA genes. An 
approach that has been used to treat these tumors is to exploit the genetic concept of synthetic 
lethality. Inhibition of PARP1 has been shown to be synthetically lethal with deficiency of BRCA1/2. 
This observation provided the impetus for PARP1 inhibitors to be tested clinically which has recently 
resulted in the approval of the first inhibitor, Olaparib, for the treatment of patients with germline 
mutations in BRCA genes. Although this approach has shown promise, multiple potential resistance 
mechanisms have been identified. In order to overcome this problem, a better understanding of 
BRCA1 and BRCA2’s molecular functions and their binding partners is needed. BRCA proteins play a 
role in in DNA repair pathway choice and in replication stress response, functions which are involved 
in sensitivity to PARP1 inhibitors. The BRCA1 protein C-terminus BRCT domains interact with multiple 
proteins and are required for BRCA1's tumor suppressor function. Through this domain, BRCA1 forms 
three mutually exclusive complexes with Abraxas, BRIP1, and CtIP, originating the BRCA1-A, -B and –C 
complexes, respectively. With this study, we decided to investigate the roles of BRCA1-A and -B 
complexes in these two mechanisms, as their role. Together, our results show that depletion of either 
Abraxas or BRIP1, and consequently, disruption of the respective complexes, is synthetically lethal 
with PARP1 inhibition. We suggest this phenotype to be a result of the role played by BRCA1-A and 
BRCA1-B in HDR, more specifically, in the DNA repair pathway choice. Moreover, BRIP1 expression, or 
the assembly of BRCA1-B, appears to influence the expression of Abraxas. Here, we also propose a 
role in replication stress response played by BRCA1-A and –B complexes. However, further 
investigation is needed to validate our findings. In a general manner, our results contribute to a full 
understanding of BRCA1 and its binding partners’ molecular functions. This knowledge is crucial to 
understand the mechanisms of resistance to the current drugs used in BRCA-deficient cells, and to 
improve the current therapeutic approaches. 
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Resumo 
 
Mutações hereditárias nos genes BRCA1 e BRCA2 representam a grande maioria dos casos 
familiares de cancro de mama e de ovário. Ao longo dos últimos 20 anos, houve um progresso 
considerável na compreensão das funções biológicas das proteínas BRCA, o que levou ao 
desenvolvimento de novas abordagens terapêuticas que visam tumores com mutações que levam à 
perda de função dos genes BRCA. Uma abordagem que tem sido usada para o tratamento deste 
tumores baseia-se no conceito genético de letalidade sintética. A inibição de PARP1 mostrou-se 
sinteticamente letal com a deficiência de BRCA1/2. Esta observação proporcionou o impulso para que 
os inibidores de PARP1 fossem testados clinicamente, o que recentemente resultou na aprovação do 
primeiro inibidor, Olaparib, para o tratamento de pacientes com mutações hereditárias nos genes 
BRCA. Embora esta abordagem tenha mostrado bons resultados, têm sido identificados vários 
potenciais mecanismos de resistência. Para superar este problema, é necessário uma melhor 
compreensão da função molecular de BRCA1 e BRCA2 e das proteínas com as quais interagem. 
BRCA1 e BRCA2 desempenham um papel fundamental na decisão entre as vias de reparação de ADN, 
“DNA repair pathway choice”, e na resposta ao stresse durante a replicação, funções que estão 
relacionadas com a sensitividade aos inibidores de PARP1. Os domínios BRCT de BRCA1 interagem 
com múltiplas proteínas e são necessários para a função supressora tumoral de BRCA1. Através deste 
domínio, BRCA1 forma três complexos mutuamente exclusivos com Abraxas, BRIP1 e CtIP, originando 
os complexos BRCA1-A, -B e -C, respetivamente. Neste estudo, decidimos investigar a importância 
dos complexos BRCA1-A e -B nesses dois mecanismos. No seu conjunto, estes resultados mostram 
que a depleção de Abraxas ou de BRIP1 e, consequentemente, a desagregação dos respetivos 
complexos, é sinteticamente letal com a inibição de PARP1. Aqui sugerimos que este fenótipo seja o 
resultado do papel desempenhado por BRCA1-A e BRCA1-B na reparação de ADN por recombinação 
homóloga, mais especificamente, na escolha da via de reparação do ADN. Além disso, a expressão de 
BRIP1, ou a formação de BRCA1-B, parece influenciar a expressão de Abraxas. Aqui, também 
propomos que os complexos BRCA1-A e -B desempenham funções na resposta ao stresse durante a 
replicação. No entanto, de forma a validar estes resultados, é necessária uma investigação mais 
aprofundada. De forma geral, estes resultados contribuem para uma compreensão completa das 
funções moleculares do BRCA1 e das proteínas com as quais forma complexos. A compreensão 
destas funções é crucial para entender os mecanismos de resistência aos tratamentos atuais usados 
em células com mutações nos genes BRCA, e para melhorar as abordagens terapêuticas correntes.
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1. Introduction 
 
1.1. DNA double-strand break repair pathway choice 
 
Our genetic material is continuously challenged by genotoxic stress. DNA lesions arise from 
exogenous and endogenous sources, generating approximately 105 lesions per cell every day 1. To 
ensure genome stability, cells have evolved the ability to sense DNA damage, activate the cell cycle 
checkpoint and initiate DNA repair. The crosstalk between both processes is known as the DNA 
damage response (DDR) and ensures that cell cycle progression is halted soon after DNA damage is 
detected, allowing the DNA repair machinery to repair the damage before cells continue with DNA 
replication and cell division 2,3. In the case of persistent DNA damage, cells undergo either apoptosis 
or senescence 4,5. Cells defective in DDR generally display heightened sensitivity towards DNA-
damaging agents and many such defects cause human disease 1.  
Of all the lesions that can occur in the DNA, double-strand breaks (DSBs) are considered to be 
the most threatening form of DNA damage, as the integrity of both strands of the DNA duplex is 
compromised simultaneously 6. Failure to faithfully repair them can result in a variety of mutations, 
including chromosomal rearrangements that are characteristic of cancer cells. The repair of DSBs is 
achieved by two mechanistically distinct processes: non-homologous end joining (NHEJ), which 
promotes direct ligation of the two broken ends, and homologous recombination directed repair 
(HDR), which requires a homologous template to regenerate the region surrounding the break (Fig. 
1). Homology searching, a central step of HDR, requires DNA 5’ end resection. The decision to resect 
is critical to DSB repair pathway choice, wherein initiation of this process commits cells to HDR while 
preventing repair by NHEJ 7,8. The choice between these two repair pathways depends on the phase 
of the cell cycle. NHEJ operates throughout the cell cycle but is particularly important in the G1 
phase, since there is no template to perform HDR. To promote NHEJ, the protein complex formed by 
53BP1 and RIF1 limits 5’ end resection through recruitment of MAD2L2 9–14. Inhibition of 5’ end 
resection allows downstream factors to localize at DSBs that, ultimately, lead to ligation of the 
broken ends by DNA ligase IV 15. However, this happens in an error-prone manner, frequently 
resulting in small insertions, deletions, substitutions and translocations 15. On the other side, HDR is 
generally restricted to the S and G2 phases when DNA has replicated and the sister chromatid is 
available as a template. Hence, in S/G2, BRCA1 localizes at DSBs and, through its binding to CtIP, 
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promotes 5’ end resection by opposing the inhibitory effect of the 53BP1 pathway 10,16–18. Then, 
BRCA2 promotes RAD51 nucleofilament formation, homology search, strand invasion, and replication 
of the genetic material 8. This allows the repair to act in an error-free fashion, promoting genome 
stability through the precise repair of DNA double-strand breaks 19. Therefore, depending on the cell 
cycle, cells must choose the appropriate pathway for DNA repair, NHEJ in G1 and HDR in S/G2. Failing 
to commit to the right choice endangers genomic integrity and can contribute to tumorigenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1- Repair of DSBs by NHEJ and by HDR. a) NHEJ operates throughout the cell cycle, being particularly 
important in G1. 53BP1 inhibits 5’ end resection through the recruitment of RIF1 and the downstream protein 
MAD2L2, preventing the promotion of HDR by BRCA1 while committing to NHEJ repair. Inhibition of 5’ end 
resection allows the KU70– KU80 complex, DNA-PKcs and the XRCC4–XLF–DNA ligase IV complex to localize at 
DSBs, leading to ligation of the broken ends by DNA ligase IV. b) HDR is restricted to the S and G2 phases of the 
cell cycle. It is initiated when BRCA1 is able to stimulate 5’ end resection by releasing the inhibitory effect of 
53BP1. CtIP then promotes 5’ end resection through the interaction with the MRN complex and stimulation of 
its nuclease activity. End resection inhibits the binding of KU70–KU80 to DNA ends, thereby also inhibiting 
NHEJ. RPA rapidly coats the ssDNA generated by DNA end resection and is then replaced by the recombinase 
RAD51, a process dependent on BRCA2. RAD51 filament formation enables homology search, duplex invasion 
and DNA synthesis. Adapted from Panier and Durocher, 2013
 20
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1.2. Targeting  Poly (ADP-ribose) polymerase (PARP) 1 in BRCA1 -deficient tumors 
  
BRCA1, a key regulator of HDR, is a tumor suppressor gene, and germline mutations of the 
human gene account for most familial cases of breast and ovarian cancer. Cells with defects in BRCA1 
lack the ability to localize RAD51 to damaged DNA and, consequently, are unable to perform HDR. As 
a result, the error-prone NHEJ takes over, leading to an accumulation of genetic aberrations, which 
likely foster tumorigenesis. The genetic concept of synthetic lethality has been exploited as an 
approach to treat BRCA-deficient tumors. Synthetic lethality describes the situation in which defects 
in either one of two genes individually is compatible with cell viability,  but when defects in the two 
are combined, lethality ensues (Fig. 2a) 21,22. Inhibition of Poly (ADP-ribose) polymerase 1 (PARP1) has 
been shown to be synthetically lethal with deficiency of BRCA1 23. PARP1 is an enzyme involved in 
DNA single-strand break (SSB) repair. Upon damage, PARP1 is recruited to the site of SSBs, where it 
binds the DNA and promotes DNA repair. PARP1 inhibition leads to accumulation of SSBs and to the 
stalling of the replication fork (RF) by trapping PARP1 on the DNA, which eventually leads to the 
collapse of the RF, causing DSBs (Fig. 2b). HDR is the preferred mechanism for repairing collapsed RFs. 
When BRCA1 is dysfunctional, alternative DNA repair mechanisms such as NHEJ are used. These 
alternative processes sometimes fail to efficiently repair the replication fork, and this is ultimately 
deleterious to the cell. Thus, cells carrying BRCA mutations are up to 1,000 times more sensitive to 
PARP1 inhibition than wild-type cells. These observations provided the impetus for PARP inhibitors 
(PARPi) to be tested clinically, which recently led to the approval of the first PARPi, Olaparib, for the 
treatment of patients with germline mutations in BRCA genes.  
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Figure 2 - Genetic concept of synthetic lethality and PARP1 inhibition in BRCA1-deficient cells. a) A genetic 
interaction in which single-gene defects are compatible with cell viability, but the combination of gene effects results in cell 
death. The first clinical exemplification of synthetic lethality in cancer was the targeting of BRCA-deficient tumor cells with 
PARPi. b) PARP1 is involved in the repair of SSBs. Upon damage, PARP1 is recruited to the site of SSBs, where it binds DNA and 
catalyses a series of PARylation events, promoting DNA repair. As part of this process, PARP1 autoPARylates, leading to its 
release from DNA. PARPi prevent the release of PARP1 from DNA, most likely by inhibiting autoPARylation. PARP1 
autoPARylates, leading to its release from DNA. PARPi prevent release of PARP1 from DNA, most likely by inhibiting 
autoPARylation. PARP1 inhibition leads to the stalling of the replication fork by accumulation of SSbs, ultimately leading to the 
collapse of the RF, causing DSBs). c) Cells repair the RF preferably by HDR. Cells deficient in BRCA1 have a dysfunctional HDR 
and, therefore, the number of stalled RFs accumulates. Cells use alternative error-prone repair mechanisms, such as NHEJ, 
which are incapable of efficiently repairing the RF, resulting in chromosomal instability and subsequent cell death. This defect 
results in a hypersensitivity of BRCA1-deficient cells to PARPi. Adapted from Lord and Ashworth, 2013 
21
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1.3. Mechanisms of resistance to PARPi in BRCA1-deficient tumors 
 
Although the use of PARPi in BRCA-deficient tumors has shown promise, emergence of drug 
resistance is a common clinical problem, affecting PARPi efficiency. Multiple potential resistance 
mechanisms have been identified. The most well-validated mechanism of resistance to PARPi seen in 
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patients with BRCA1 mutations is genetic reactivation of BRCA1-mutated alleles which can occur 
because of alternative splicing, retromutations, or secondary mutations restoring BRCA1’s reading 
frame. It was also shown that transcription of silenced BRCA1 alleles can be restored upon promoter 
demethylation or gene fusions to distant promoters 24–26. Alternatively, resistance to inhibition of 
PARP1 can also result from BRCA1-independent restoration of HDR. The most well-studied and 
validated mechanism was the finding that loss of 53BP1 rescues the HDR deficiency, proliferation 
defect and PARPi hypersensitivity of BRCA1-deficient cells 27,28. 53BP1 deletion allows the resection of 
broken DNA ends, leading to error-free repair by HDR. These findings led to novel mechanistic 
insights in DSB repair and to date loss of several downstream effector proteins of 53BP1 have been 
shown to render BRCA1-deficient cells resistant to PARPi, including MAD2L2 13,14, RIF1 10,11, PTIP 12, 
Artemis 29. Besides, recently it was shown that BRCA1-mutant tumors may also acquire PARPi 
resistance by amplification of TIRR, involved in the regulation of 53BP1, leading to overexpression of 
TIRR, which results in impaired function of 53BP1 and, subsequently, in HDR restoration 30. These 
findings reveal that the DNA damage response pathway can be rewired to restore HDR. Independent 
of HDR, recent studies have shown that BRCA1 has DSB-independent functions during replication 
stress and it has been proposed that resistance to PARPi might also occur due to protection of RF 31. 
However, many other mechanisms of resistance are yet to be found. A better understanding of how 
BRCA1 contributes to DNA damage and replication stress pathways will help clarify how BRCA1-
deficient tumors can acquire resistance to PARP1 inhibitors and, eventually, can help to find new 
therapeutic targets. 
 
1.4. BRCA1: a master regulator of genome integrity 
 
BRCA1 is intimately involved in diverse cellular processes that ensure genome stability and 
promote cell survival. Through its ability to associate with multiple proteins, BRCA1 has important 
roles in the DNA damage response, including cell cycle checkpoint control and DNA repair. Moreover, 
recent reports also demonstrate a new role of BRCA1 in the replication stress response 31–34. BRCA1, 
which is located on chromosome 17q21, is a large protein of 1,863 amino acids. It harbors two 
important highly conserved domains at each end of the protein, an amino-terminal RING domain and 
two BRCT domains at its carboxyl terminus. The fact that these domains are frequently targeted by 
many clinically important mutations indicates that they are essential for BRCA1 function 35–37.  The 
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RING domain is required for heterodimerization of BRCA1 with BARD1. BRCA1-BARD1 
heterodimerization is required for their stability in vivo and for their nuclear localization 38,39. This 
heterodimer has E3 ubiquitin ligase activity and BRCA1/BARD1-dependent ubiquitin conjugates occur 
at sites of DNA DSBs suggesting that the BRCA1-BARD1 heterodimer is important for DNA repair and, 
therefore, is important for the tumor suppressor activity of BRCA1 40. On the other hand, the BRCA1 
BRCT domains are conserved in multiple DDR proteins domains and are thought to be integral to 
BRCA1’s ability to regulate a diverse set of cellular processes that confer its tumor-suppressing 
activity. The paired BRCT domains form a binding site that recognizes a phospho-SPxF (S, serine; P, 
proline; × varies; F, phenylalanine) motif and mediates the association of BRCA1 to phosphorylated 
proteins Abraxas, BRIP1 and CtIP. Cell cycle-dependent phosphorylation of these proteins at the 
serine residue of their p-SPxF motif by CDK is required for BRCA1 interaction. Since, these proteins 
associate with the same binding site of BRCA1, they form three mutually exclusive different 
complexes known as BRCA1-A (Abraxas), -B (BRIP1) and -C (CtIP) (Fig. 3).  Although it remains elusive 
how these complexes are involved in BRCA1 signaling, it appears that these three complexes partially 
undertake BRCA1’s role in cell cycle checkpoint and in DNA repair, that maintain genome stability 
and, thus, may be essential for the tumor suppression function of BRCA1. Of the three BRCA1-
forming complexes, BRCA1-C is the only one known to actively participate in HDR, as it is required for 
the fine-tuning of DNA end resection 10,41,42. Besides, loss of CtIP has been shown to render cells 
sensitive to PARP inhibition 43. On the contrary, the exact role of BRCA1-A and -B in HDR still requires 
further study. 
 
Figure 3 – BRCA1 Complexes. BRCA1-A complex is composed of BRCA1, RAP80, Abraxas, MERIT40, BRCC45, and 
BRCC36. BRCA1-B is composed of BRCA1, TopBP1, and BRIP1. BRCA1-C comprises BRCA1, CtIP and MRE11–
RAD50–NBS1 complex (MRN complex).  
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1.5. Roles of BRCA1-A and -B complexes  
 
The BRCA1-A complex is composed by the ubiquitin interacting motif (UIM) containing 
protein RAP80, adapter protein Abraxas, the scaffolding proteins MERIT40 and BRCC45, and the 
deubiquitinating enzyme (DUB) BRCC36 37. The phosphorylation of the C-terminal serine (p-S406) of 
the SPxF motif of Abraxas is responsible for the interaction with the BRCT domain of BRCA1 44. 
Abraxas acts as a central adapter linking BRCA1 to other components in the BRCA1-A complex and it 
was demonstrated to play a role in tumor suppression 45. BRCA1 is targeted to DSBs sites through its 
association with the A complex, which in turn localizes at DSBs through the UIMs of RAP80, which 
recognize the Lys63 poly-ubiquitin chains of the histone H2AX 44,46. This process is initiated by ATM-
mediated H2AX phosphorylation near the DNA lesions and is required for the DDR. Additionally, 
BRCA1-A has been shown to be required for preventing over-resection of DSB ends, a process 
dependent on the Lys63-deubiquiting function of the enzyme BRCC36 47–49. The BRCA1-A complex is 
also involved in the G2/M checkpoint in response to ionizing radiation (IR)-induced DNA damage, 
whereas BRCA1-B seems to be necessary for the S-phase checkpoint in response to replication stress 
50–52. BRCA1-B is composed by the helicase BRIP1 and by TOPBP1. The interaction of BRIP1 with 
BRCA1 requires the phosphorylation of its C-terminal serine (p-S990) of its SPxF motif 53. Defects in 
BRIP1 lead to reduced HDR and delayed DNA repair 54. Binding of BRIP1 to TOPBP1 is important for 
proper replication, being a requirement for replication checkpoint control, as it mediates activation 
of ATR-dependent phosphorylation events in response to replication stress. Furthermore, it was 
suggested that a specific interaction between TOPBP1 and BRIP1 is likely to be required for the 
extension of ssDNA regions and RPA loading following replication stress 52. As a member of the 
Fanconi anemia (FA) proteins, BRIP1 (also known as FANCJ) also plays a role in DNA interstrand 
crosslink (ICL) repair 55. Moreover, it was shown that loss of BRCA1-BRIP1 interaction promotes a 
switch from HDR to polη-dependent bypass 56.  
Consistent with the hypothesis that Abraxas and BRIP1 contribute to BRCA1’s role in tumor 
suppression, both have been associated with breast and ovarian cancer 45,54,57–60. Thus, clarifying the 
diverse functions of BRCA1-A and BRCA1-B, besides helping understanding the molecular function of 
BRCA1, its binding partners and the involved molecular pathways, can result in a meaningful impact 
on disease treatment. 
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2. Objectives 
 
 
2.1. Main Objective 
 
Understand the role of BRCA1-A and -B complexes in DNA repair pathway choice and 
in replication stress. 
 
 
2.2. Specific Objectives 
 
 Disruption of BRCA1-A and -B complexes using the CRISPR-Cas9 system to generate 
knockout single clones of ABRAXAS and BRIP1. 
 
 Test sensitivity of knockout clones to PARPi (Olaparib) by long term clonogenic assays. 
 
 Analysis of the effect of the disruption of BRCA1-A and -B complexes on DNA repair 
pathway choice. 
 
 Analysis of replication stress markers in knockout clones. 
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3. Materials and Methods 
3.1. Cell culture and clonogenic survival assays 
 
For this study, two cell lines were used: HeLa and HEK293T.  HeLa cells are derived 
from cervical cancer cells. HEK293T cells are derived from human embryonic kidneys and are 
transformed with large T antigen. All cell lines were maintained in DMEM with 100U penicillin, 0.1 
mg/ml streptomycin, 2mM L-glutamine and 10% fetal bovine serum. All cells were maintained in a 5% 
CO2 incubator at 37
oC. 
For clonogenic assays, cells were seeded in 6cm dish at density of 20,000 per dish in the 
presence of PARPi (Olaparib, 1 or 3µM) or DMSO. Medium was refreshed every 5 days. After 12 days, 
plates were fixed with 10% formalin and stained with a 0.1% (w/v) crystal violet solution. Colony 
quantification was performed by crystal violet extraction with 10% (v/v) acetic acid and absorbance 
(590nm) was measured. 
 
3.2. Cloning and CRISPR–Cas9 genome editing 
 
CRISPR guides were designed using online tool Benchling (https://benchling.com). The 
sequence of the single guides (sgRNA) used for the generation of knockouts are: Abraxas KO clone #9-
1: 5’- GAGGGGGAGAGTACGTCGG - 3’; Abraxas KO clone #14-2: 5’- CCTCAACACGGACTCGGACA - 3’; 
BRIP KO clone #7-3 and #8-7: 5’- TCTGAATATACAATTGGTG- 3’. In order to clone the guide sequence 
into the sgRNA, the oligos were synthetized in the form: 5’ – CACCGNNNNNNNNNNNNNNNNNNNN – 
3’ and the reverse complement 5’ – AAACNNNNNNNNNNNNNNNNNNNNC – 3’. The cloning was 
based on the approach developed by the Yamamoto lab 61. To anneal the oligos, 1 µl of each oligo 
(100µM) was added to 8 µl water, incubated at 95oC for 5 minutes and left at room temperature for 
1h. Afterwards, 1.5 µl of vector pX330-U6-Chimeric_BB-CBh-hSpCas9 62 (25ng/µl) (Addgene plasmid # 
42230) were added to 2.5 µl of annealed oligos (10 µM), 0.5 µl of the restriction enzyme BbsI (NEB), 
0.5ul of Quick ligase (NEB), 1µl of 10x T4 DNA ligase buffer (NEB), and 4 µl of water were mixed and 
incubated at 37oC for 5min followed by 10 min at 16oC. This cycle was repeated three times. In order 
to perform an extra digestion to ensure complete digestion of the empty plasmid, 0.5 µl of BbsI and 1 
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µl of 10X Buffer G (Thermo Fisher Scientific) were mixed and incubated at 37oC for 1h followed by an 
incubation at 80oC for 5min. Next, 2 µl of the cloning product were added to 25µl of competent cells 
XL10-Gold (Agilent Technologies) and transformed using heat shock. After incubation in S.O.C. 
medium (Thermo Fisher Scientific) at 37oC during 1h, cells were plated in LB agar plates with 100 
µg/mL ampicillin and incubated overnight at 37oC. O the next day, 8 colonies per sgRNA were picked 
and the plasmids were isolated using the QIAprep Spin Miniprep Kit (QUIAGEN) as suggested by the 
manufacturer. The sgRNA insertion was accessed by Sanger sequencing.  
For generation of knockout clones, HeLa cells were plated in 6-well plates at a density of 
150,000 cells per well.  The next day cells were co-transfected with 3µg of the plasmid containing the 
sgRNA and Cas9 and with 1 µg of the donor plasmid. After 3 days, medium was changed and 
Blasticidin (10µg/ml) was added. 10 days after addition of selection, resistant colonies were isolated 
(one colony per well) and expanded. Genomic DNA was isolated, and cells lysates were used for 
protein analysis.  
 
3.3. shRNA-mediated silencing 
 
Glycerol stocks containing hairpins were obtained from MISSION shRNA library (Sigma, TRC) 
clones. Plasmid DNA isolation was carried out with the HiPure Plasmid Midiprep Kit (Invitrogen), as 
suggested by the manufacturer. HeLa cells were transduced with the following pLKO-puro or pLKO-
blast shRNA lentiviral particles: 53BP1: 5’ -GATACTTGGTCTTACTGGTTT- 3’; RIF1: 5’-
CGCATTCTGCTGTTGTTGATT-3’; MAD2L2: 5’-CCGGAGCTGAATCAGTATAT-3’; BRCA1: 5’- 
GCCCACCTAATTGTACTGAAT -3’. 
3.4. Transfections and lentiviral infections 
 
For generation of knockout clones, we used the TransIT®-LT1 transfection reagent (Mirus) 
and we followed the manufacturer’s protocol with slight changes: we used a ratio of 2:1, i.e., 6 µl of 
TransIT®-LT1 transfection reagent to 3µg of plasmid. Cells were cultured in DMEM as described in 3.1. 
For generation of lentiviral particles we seeded HEK293T cells at a density of 4,000,000 cells 
per 10cm dish. The following day, HEK293T cells were transfected as follows: a mix containing the 
lentiviral packaging vectors (pVSVG – 3.5 µg, pRRE – 6.5 µg and pREV – 2.5 µg), the pLKO-puro or 
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pLKO-blast shRNA-containing vector (10 µg) and 0.25M of CaCl2 in MilliQ water was prepared in a 
volume of 500 µL, to which 500 µL of 2xHBS (280 mM NaCl, 1.5 mM Na2PO4.7H2O, 50 mM HEPES; pH 
7) was added dropwise, while vortexing at maximum speed, and immediately added to the cells. 
Culture medium was refreshed 16h before refreshing the culture medium. 32h post transfection, 
lentiviral particles were obtained by filtering the supernatant of 293T cells. For lentiviral transduction, 
HeLa cells were seeded at a density of 200,000 per well in 6-well plates. After 24h, cells were 
transduced with shRNA-containing lentivirus. In order to increase transduction efficiency, polybrene 
was added to the cells in a final concentration of 8µg/ml.  16h post infection, medium was refreshed 
and cells selection was added (Puromycin (2µg/ml) or Blasticidin (10µg/ml)). Cells were cultured in 
DMEM as described in 3.1. 
 
3.5. DNA extraction and PCR 
 
Genomic DNA from CRISPR-ca9 single clones was isolated using DNeasy Blood & Tissue Kits 
(QUIAGEN), as suggested by the manufacturer. For analysis of blasticidin resistance cassette 
insertion, Phusion High-Fidelity DNA Polymerase kit (Thermo Fisher Scientific) was used. For analysis 
of insertion into ABRAXAS gene, the following set of primers were used: Fw 5’-
CCTGTCAACCGTGTTCATTTTGATAGC3’ and Rv 5’-GCCCAAGTTTCCACAGCTACAG-3’. For analysis of 
insertion into Brip1 gene, the following set of primers were used: Fw 5’-ACGGAGTTGTAGAGAGAGAG-
3’ and Rv 5’- AGTAGTTTCCCAGAGGTTAGA-3’. PCR product analysis was performed by agarose gel (1% 
w/v) electrophoresis.  
 
3.6. Protein extraction and Western Blot 
 
Cells were seeded at a density of a 1,000,000 cells in a 6cm dish. Whole-cell lysates were 
prepared by scraping cells in 2x SDS sample buffer. Protein concentration was determined for each 
sample using the standard BCA protein assay (Pierce). Protein concentrations were normalized to the 
least concentrated sample, and samples were separated on precast 4-12% Bis-Tris gels (Invitrogen). 
Proteins were then transferred on to nitrocellulose blotting membranes (GE Healthcare) and blocked 
in 5% milk, or 5% BSA solutions in 0.1% PBS-Tween20. Primary antibodies were diluted in 1% milk or 
12 
 
5% BSA solutions in 0.1% PBS-Tween20 and incubated overnight at 4°C. Membranes were washed 
three times with 0.1% PBS-Tween20 and incubated with secondary antibodies for 1h at room 
temperature. Western blotting was performed using horseradish peroxidase (HDRP)-conjugated 
secondary antibodies (1:7000), which were detected by enhanced chemiluminescence (ECL) (Thermo 
Fisher Scientific). Blots were developed using Amersham Hyperfilm ECL films (GE Healthcare). Primary 
antibodies used: Abraxas (A302-181A, Bethyl, 1:1000); BRIP1 (ab151509, Abcam, 1:1000);  BRCA1 (sc-
6954, Santa Cruz, 1:200); 53BP1 (A300-272A, Bethyl, 1:2000); CtIP (22838, Santa Cruz, 1:500); MAD2B 
(135977, Santa Cruz, 1:200); Histone H2B (07-371, Millipore, 1:2000); Histone H3 (ab1791, Abcam, 
1:10000). Histones H3 and H2B were blotted as loading controls.  
 
3.7. Immunofluorescence 
 
 Cells were seeded on 8-well chamber slides (Millipore) and allowed to adhere. In order to 
visualize DDR foci, cells were irradiated with 5 Gy and fixed after 3h. For replication stress 
experiments: to visualize γ-H2AX staining, cells were fixed after 3h of treatment with  hydroxyurea 
(HU) (2mM); for staining with Bromodeoxyuridine (BrdU), cells were cultured with BrdU-containing 
medium (10µg/ml) for 30h, and then released in new medium with HU (2mM) and fixed after 3h of 
treatment. For BrdU staining, cells were washed with 0.5% Triton/PBS for 3min before fixation. Cells 
were fixed in 4% paraformaldehyde/PBS, for 10 min.  Cells were permeabilized for 10 min in 0.5% 
Triton/PBS and incubated for 1h with blocking solution (0.02% Triton, 5% NGS, 5% FCS in PBS). 
Primary antibodies were diluted in blocking solution and incubated overnight at 4°C. The following 
day, cells were washed three times with 0.02% Triton/PBS and incubated with fluorophore-
conjugated secondary antibodies (Alexa Fluor 488 anti-rabbit IgG; Alexa Fluor 568 anti-mouse IgG; 
Invitrogen), diluted 1:500 in blocking solution, for 1h at RT. After three washes with 0.02% 
Triton/PBS, slides were mounted in Vectashield (Vector Laboratories) containing DAPI. Fluorescence 
images were obtained on a Leica SP5 confocal system equipped with Ar, Kr and HeNe lasers. Images 
were acquired using a 63×, 1.32 NA oil immersion objective (Leica), and processed with LAS-AF 
software. Primary antibodies used: 53BP1 (A300-272A, Bethyl, 1:2000); Cyclin A (MS-1061-S0, 
Thermo Fisher Scientific, 1:500); Cyclin A (sc-751, Santa Cruz, 1:100); RIF1 (A300-569A, Bethyl, 
1:1000); γ-H2AX (Ser 139) (5636, Millipore, 1:500); BrdU (NA61, Calbiochem, 1:50); CENPF 
(SAB2702181, Sigma, 1:500) 
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4. Results 
4.1. Generation of knockout clones of ABRAXAS and BRIP1  
 
Abraxas and BRIP1 are the central adapters of the BRCA1-A and –B complexes, respectively. 
In order to investigate the role of BRCA1-A and -B complexes in DNA repair pathway choice and in 
replication stress, we used the CRISPR–Cas9 system to generate Abraxas and BRIP1 knockout (KO) 
clones in HeLa cells, in order to be used as tools for this study. Previously, Lackner and colleagues 
described a strategy that enables the tagging of endogenous loci using the CRISPR-cas9 system and 
one generic donor plasmid 63. The donor plasmid contains a tag of interest which is flanked by two 
sgRNA cleavage sites that correspond to a genomic locus in Zebrafish (tia1l) that is absent in human 
cells. The donor plasmid also encodes a U6 promoter driving the expression of the tia1l sgRNA. When 
cells are transfected with Cas9, the donor plasmid and a sgRNA specific to the region of the gene 
where the tag should be incorporated, the tag is released from the plasmid and subsequently 
integrated into the gene of interest by NHEJ. To obtain our knockout clones, we made use of this 
approach by using the donor plasmid with a Blasticidin resistance (BlastR) cassette as a tag (Fig.4a). 
Co-transfection of the donor plasmid with a cas9-expressing plasmid 62, in which we cloned a sgRNA, 
allowed us to use Blasticidin to select the clones where the plasmid was integrated. As a negative 
control, we transfected HeLa cells with donor plasmid and with the cas9-expressing plasmid , without 
sgRNA cloned. We design 3 sgRNA per gene, however, only 2 of the sgRNAs targeting ABRAXAS and 1 
sgRNA targeting BRIP1 efficiently generated Blasticidin-resistant colonies. The resistant colonies were 
isolated and screened using western blot and PCR (Fig.4b,c,d). After analysis, two clones per gene 
were selected (Abraxas KO # 9-1 and # 14-2; BRIP1 KO # 7-3 and # 8-7) and used as tools for the 
following experiments.  
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Figure 4 – Identification of Abraxas and BRIP1 knockout clones in HeLa cells. a) Schematic representation of our CRISPR-
Cas9 approach. Adapted from Lackner et al. 2015 
63
. b) Exemplification of how a PCR followed by agarose gel 
electrophoresis can identify knockout clones. For comparison, PCR products from a control, a knockout (BRIP1 KO # 8-7), 
and heterozygous sample are shown. Blue arrow indicates the size of the fragments without tag insertion, and orange arrow 
indicates the size of the fragments with tag insertion. Samples that only display a band, corresponding to the upper 
fragment (with insertion of tag), have the targeting gene disrupted. Samples that exhibit both fragments don’t have tag 
insertion in all alleles and, thus, were considered to be heterozygous and discarded. c), d) Western-blot analysis 
representing protein expression of knockout clones of Abraxas and BRIP1, respectively. For comparison, samples from a 
control, knockout and heterozygous clones are shown. Histone H2B was blotted as a loading control. 
 
 
4.2. Sensitivity of knockout clones to Olaparib 
 
BRCA1 dysfunction, results in cells markedly sensitized to inhibition of PARP1 enzymatic 
activity. Hence, we decided to test if our knockout clones, where the BRCA1-binding complexes A and 
B are disrupted, are also sensitive to PARP1 inhibition. Cells were treated for 12 days with 1 µM 
700 bp 
1500 bp 
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Olaparib. As positive control, cells transduced with shBRCA1 lentiviral particles were also treated. As 
expected, while untransduced cells don’t show sensitivity to Olaparib, cells transduced with shBRCA1 
show toxicity to the drug (Fig.5). On the other hand, both Abraxas and BRIP1 knockout clones were 
sensitive to Olaparib, although not as sensitive as the cells transduced with shBRCA1 lentiviral 
particles (Fig.5). These results suggest that Abraxas and BRIP1 and, therefore, their respective 
complexes (BRCA1-A and –B, respectively), might be important for HDR.   
Tumor cells are known to have the ability to adapt upon stress, overcome cell death, and to 
become drug-resistant. As HeLa cells are a tumor-derived cell line, we expected cells to easily adapt 
to knockout of Abraxas and BRIP1. Therefore, as the experiments in this study were performed in 
different time-points, in each of the following chapters we display a clonogenic assay as control, 
which was performed in parallel with the respective experiments, where sensitivity to Olaparib can 
be used as a read-out of adaptation of cells to the stress generated by depletion of these proteins. 
 
 
Figure 5 – Sensitivity to Olaparib. a) Crystal violet staining of untransduced HeLa cells, HeLa cells transduced with shBRCA1 
lentivirus particles, and Abraxas and BRIP1 knockout clones treated with DMSO (vehicle) or Olaparib (1µM) during 12 days. 
b) Quantification of cell survival from a) by measurement of extracted crystal violet absorbance at 590 nm. Graph shows cell 
survival ratio between Olaparib and DMSO treatment. All values were normalized by the mean of the blank. Mean is shown 
from three independent measurements.  
 
4.3. Analysis of the DNA repair pathway choice upon Abraxas and BRIP1 depletion  
Since depletion of Abraxas and BRIP1 appears to be important for HDR, we investigated if 
these proteins play a role in pathway choice.  In S/G2 phases of the cell cycle, when BRCA1 is 
depleted, 53BP1 and downstream factors are no longer suppressed, allowing their localization at 
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DSBs sites. Therefore, NHEJ repair can takeover. In order to investigate if BRCA1-A and –B complexes 
are involved in DNA repair pathway choice, we analyzed nuclear foci formation of 53BP1 and the 
downstream factor RIF1 in S/G2 phases of the cell cycle, after induced DNA damage by ionizing 
radiation (5 grey (Gy)). Untransduced HeLa cells, cells transduced with shBRCA1 lentivirus, and two 
Abraxas and BRIP1 knockout clones irradiated and non-irradiated were fixed after 3 hours and 53BP1 
and RIF1 foci formation was analyzed by immunofluorescence (IF). Cells were co-stained for CENPF. 
CENPF is a kinetochore protein and was used as a cell cycle marker as its expression is induced at 
G1/S, increases during S phase until it peaks at G2 and starts to be degraded at mitosis 64. In order to 
distinguish between G1 and S/G2 cells, the mean fluorescence intensity (MFI) of CENPF was 
quantified for all the cells and a threshold was set. Hence, low CENPF expressing cells were 
considered to be in G1 and high CENPF expressing cells in S/G2. Generally, 53BP1 and RIF1 formed 
less foci in high CENPF cells when compared with low CENPF cells, as could be expected due to the 
opposition imposed by BRCA1 during S/G2 (Fig.6c, d). Upon knockdown of BRCA1, cells showed 
increased 53BP1 and RIF1 foci formation during S/G2, when compared to the parental untransduced 
cells (Wt), as it was expected (Fig.6). Abraxas knockout clones both showed increased 53BP1 foci 
formation (Fig.6a,c), however, only the clone #14-2 showed a significant increase of RIF1 foci in S/G2 
(Fig.6b,d). On the other hand, only BRIP1 clone #8-7 showed significant increase of 53BP1 foci 
(Fig.6a,c), whereas  both clones showed increase of RIF1 foci in S/G2 (Fig.b,d).  
Looking at the control clonogenic assay (as explained in the previous section, 4.2.), cells 
transduced with shBRCA1 showed increased toxicity, when compared with untransduced Wt, as 
expected (Fig.7). Moreover, all the knockout clones displayed sensitivity to the inhibition of PARP1, 
although not to the same extent as cells with BRCA1 knockdown, with the exception of the Abraxas 
knockout clone #14-2, which appears to be as sensitive as cells transduced with shBRCA1 (Fig.7). This 
corroborates with the observation that the clone also has similar or higher levels of 53BP1 foci than 
cells with BRCA1 knockdown. However, the same doesn’t happen with RIF1 foci formation.  Although 
the results obtain from analysis of foci formation were not completely reproducible between 53BP1 
and RIF1, in general, the number of foci in S/G2 increased in both experiments, which might indicate 
that BRCA1-A and –B complexes are involved in DNA repair pathway choice.  
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Figure 6 – 53BP1 and RIF1 foci formation. a) Representative images of  53BP1 and b) RIF1 nuclear foci in the indicated cells,  
3h after exposure to ionizing radiation (5 Gy), visualized by immunofluorescence. The cells shown were consider to express 
high CENPF indicating to be in the S/G2 of the cell cycle. Scale bar: 14µm. c) Quantification of 53BP1and and d) RIF1 foci in 
more than 100 cells exposed to 5 Gy, per condition. Each dot represents one cell (n=1; mean ± s.d.). Statistical analysis was 
performed in GraphPad Prism 7 using a two-way ANOVA test. Results from statistical analysis of “High CENPF” group are 
displayed in the graphic. n.s., not significant; *, P < 0.05; **, P < 0.01 ; ****, P < 0.0001. 
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Figure 7- Clonogenic assay in the presence of 3µM Olaparib at the time of experiments from Fig.6. a) Crystal violet staining 
of untransduced HeLa cells, HeLa cells transduced with shBRCA1 lentivirus particles, and Abraxas and BRIP1 knockout clones 
clones treated with DMSO (vehicle) or Olaparib (3µM) during 12 days. b) Quantification of cell survival from a) by 
measurement of absorbance extracted crystal violet at 590 nm. Graph shows cell survival ratio between Olaparib and DMSO 
treatment. All values were normalized by the mean of the blank. Mean is shown from three independent measurements. 
 
As referred to previously, restoration of HDR is a mechanism by which BRCA1-deficient tumor 
cells can acquire resistance to PARP1 inhibitors. One of the best studied factors that leads to HDR 
restauration, and resistance of these cells to PARP1 inhibition, is 53BP1 loss 27,28. Because knocking 
out Abraxas and BRIP1 appears to lead to sensitivity to PARP1 inhibition, and because depletion of 
these proteins leads to increase of 53BP1 and RIF1 foci formation upon DNA damage, as occurs in 
BRCA1-deficient cells, we decided to investigate if depletion of 53BP1 would also rescue the toxicity 
of PARP1 inhibition in the Abraxas and BRIP1 knockout clones.  To this end, we silenced 53BP1 with 
shRNA in WT mother, in cells transduced with shBRCA1 and in the two Abraxas and BRIP1 knockout 
clones and performed a clonogenic survival assay and analyzed protein levels by Western Blot. 
Unfortunately, single knockdown of 53BP1 led to some degree of lethality, and co-knockdown of both 
BRCA1 and 53BP1 didn’t rescue the lethality of BRCA1-knockdown cells to Olaparib, opposite to what 
was expected (Fig.8a,b). On the other hand, knockdown of 53BP1 in Abraxas knockout clones led to 
the rescue of one of the two clones (KO #9-1), and both BRIP1 clones (Fig.8a,b). Contrarily, 
knockdown of 53BP1 in Abraxas knockout #14-2 led to higher toxicity in Olaparib (Fig.8a,b). 
Moreover, 53BP1 knockdown appears to lead to slightly impaired growth in knockout clones, which is 
revealed by the diminished number of cell colonies upon treatment with the vehicle, when compared 
with the corresponding untransduced clones in the same condition. Furthermore, analysis of protein 
levels, revealed a decrease in Abraxas in cells transduced only with sh53BP1, co-transduced with 
sh53BP1 and shBRCA1. The same reduction in Abraxas protein levels was observed in BRIP1 knockout 
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clones, both untransduced and transduced with sh53BP1, when compared with untransduced (Wt) 
mother cells or with BRCA1 knockdown cells (Fig.8c). Oppositely, BRIP1 protein levels didn’t change in 
any of the other conditions (Fig.8c).  Protein expression levels of CtIP, another BRCA1-forming 
complex protein (BRCA1-C), involved in the fine-tuning of DNA end resection10,41,42, was also analyzed. 
CtIP expression levels increased in cells transduced only with sh53BP1, co-transduced with sh53BP1 
and shBRCA1, and in Abraxas and BRIP1 knockout clones, both untransduced and transduced with 
sh53BP1, when compared with untransduced (Wt) mother cells or with BRCA1 knockdown cells 
(Fig.8c).  
Since, in contrast to literature, knockdown of 53BP1 didn’t rescue the lethality of PARP1 
inhibition in BRCA1 knockdown cells, we decided to repeat the experiment with cells transduced with 
shMAD2L2. MAD2L2, is a downstream partner of 53BP1, involved in the suppression of 5’-end 
resection, and its loss in BRCA1-deficient tumor cells was shown to lead to resistance to PARP1 
inhibitors13,14. Knockdown of MAD2L2 led to slight impaired growth in cells co-transduced with 
shBRCA1 and shMAD2L2 and in knockout clones, which is revealed by the diminished number of cell 
colonies upon treatment with the vehicle, when compared with the corresponding untransduced 
clones in the same condition, as shown in the clonogenic assay (Fig.9a,b). Single knockdown of 
MAD2L2 doesn’t lead to lethality, and co-knockdown of both BRCA1 and MAD2L2 did rescue the 
lethality of BRCA1-knockdow cells to Olaparib, consistent with the literature (fig.9a,b). Additionally, 
knockdown of MAD2L2 rescued the lethality of PARP1 inhibition in the two clones of both Abraxas 
and BRIP1 knockout cells (Fig.9a,b). However, the knockout of Abraxas clones was no longer visible by 
western blot analysis, although still sensitive to Olaparib. Additionally, as shown with 53BP1 
knockdown, knockdown of MAD2L2 led to a decrease of Abraxas protein expression levels in cells 
transduced only with shMAD2L2, and in BRIP1 knockout clones, both untransduced and transduced 
with shMAD2L2, when compared with untransduced (Wt) mother cells (Fig.9c). Yet, it did not lead to 
decreased Abraxas protein expression levels in cells with BRCA1 and MAD2L2 knockdown, but it led 
to reduced levels in cells transduced only with shBRCA1, contrarily to the results obtained in the 
previous experiment (Fig.8c,9c). BRIP1 protein levels also didn’t change, as upon 53BP1 knockdown 
(Fig.8c,9c). Consistent with the results obtain with 53BP1 knockdown, CtIP expression levels also 
increased, although not so clearly, in cells transduced only with shMAD2L2, co-transduced with 
shMAD2L2 and shBRCA1, and in Abraxas and BRIP1 knockout clones, both untransduced and 
transduced with shMAD2L2, when compared with untransduced (Wt) mother cells or with BRCA1-
knockdown cells (Fig.8c,9c).  
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Figure 8- Knockdown of 53BP1 in knockout clones. a) Crystal violet staining of untransduced HeLa cells, HeLa cells 
transduced with shBRCA1 lentivirus particles, and Abraxas and BRIP1 knockout clones treated with DMSO (vehicle) or 
Olaparib (3µM) during 12 days, upon 53BP1 knockdown. b) Quantification of cell survival from a) by measurement of 
extracted crystal violet absorbance at 590 nm. Graph shows cell survival ratio between Olaparib and DMSO treatment. All 
values were normalized by the mean of the blank. Mean is shown from three independent measurements. c) Protein 
expression analysis by western blot of the cells analyzed in a). Histone H3 was blotted as a loading control. LE, low exposure; 
HE, high exposure. 
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Figure 9 - Knockdown of MAD2L2 in knockout clones. a) Crystal violet staining of untransduced HeLa cells, HeLa cells 
transduced with shBRCA1 lentivirus particles, and Abraxas and BRIP1 knockout clones treated with DMSO (vehicle) or 
Olaparib (3µM) during 12 days, upon 53BP1 knockdown. b) Quantification of cell survival from a) by measurement of 
extracted crystal violet absorbance at 590 nm. Graph shows cell survival ratio between Olaparib and DMSO treatment. All 
values were normalized by the mean of the blank. Mean is shown from three independent measurements. c) Protein 
expression analysis by western blot of the cells analyzed in a). Histone H3 was blotted as a loading control.  
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4.4. Analysis  of replication stress after treatment with hydroxyurea  
 
 
Replication stress is the slowing or stalling of replication fork progression and/or DNA 
synthesis, and can be generated by a wide range of physical obstacles, usually resulting in the 
formation of stretches of ssDNA 65. This ssDNA frequently forms when the replicative helicase 
continues to unwind the parental DNA after the polymerase has stalled 66. Recently, it has been 
demonstrated that BRCA1 plays a role during replication stress and its loss has been shown to lead to 
replication fork instability 31–34. Thus, we decided to investigate if Abraxas and BRIP1 also play a role 
in replication stress response. For this end, we tested if our Abraxas and BRIP1 knockout clones 
would show an increase of replication stress markers after treatment with hydroxyurea (HU). HU 
depletes the cells of dNTPs, which initially results in stalled replication forks that, after prolonged 
treatment, collapse into DSBs. Therefore, we treated untransduced (Wt) mother cells, cells 
transduced with shBRCA1, and each two knockout clones of both Abraxas and BRIP1, for 3 hours with 
2mM HU, which led to the stalling of active RFs, after which cells were fixed and pan-nuclear γ-H2AX 
was visualized by IF (Fig.10a). Pan-nuclear γ-H2AX reflects a generalized activation of the ATR 
pathway - a conserved signal transducer involved in replication stress and can be used as a marker of 
replication stress 67. Again, as in 4.3., the MFI of CENPF was quantified for all the cells and a threshold 
was set, allowing to distinguish cells in S/G2.  Quantification of cells with high expression of CENPF 
revealed no difference between conditions in untreated cells (data not shown). Contrarily, upon 
treatment with 2mM HU, cells with BRCA1 knockdown and both Abraxas knockout clones showed a 
significant decrease of γ-H2AX relative intensity (HU/NT) when compared with untransduced (Wt) 
cells (Fig.10a). On the other side, only BRIP1 knockout clone #8-7 showed a reduction of γ-H2AX 
relative intensity, whereas #7-3 didn’t show a significant difference with untransduced (Wt) cells 
(Fig.10a). Nevertheless, #7-3 didn’t show sensitivity to Olaparib, oppositely to the other knockout 
clones, which might reveal that it acquired resistance and explains why this clone doesn’t show a 
decrease of γ-H2AX like the other clones do (Fig.11a,b). 
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Figure 10 - Analysis of replication stress after treatment with HU. a) Quantification of MFI of γ-H2AX. Cells untreated (NT) 
and cells treated with 2 mM HU were fixed after 3 hours. b) Analysis of ssDNA by quantification of the MFI of BrdU. Cells 
were cultured with BrdU-containing medium (10µg/ml) for 30h, and then released in new growth medium with, or without 
(NT), 2mM HU and fixed after 3h. Only cells with high CENP expression were used for calculations. More than 100 cells per 
condition were used for calculations. The ratio between cells treated (HU) and untreated (NT) is displayed in the graphics 
(mean ± s.d.). Statistical analysis was performed in GraphPad Prism 7 using a two-way ANOVA test. Results from statistical 
analysis of the “High CENPF” group are displayed in the graphic. n.s., not significant; *, P < 0.05; ***, P < 0.001 ; ****, P < 
0.0001. 
 
However, because γ-H2AX can be generated by several kinases, which detect different types 
of DNA damage throughout the cell cycle, pan-nuclear γ-H2AX cannot be considered a specific marker 
of replication stress 65. On the other hand, detection of ssDNA during S phase is a specific marker of 
replication stress. In order to quantify ssDNA, we cultured untransduced (Wt) mother cells, cells 
transduced with shBRCA1, and each two knockout clones of both Abraxas and BRIP1 in BrdU-
containing medium (10µg/ml) for 30h, and then released in new growth medium with or without 
2mM HU for 3h, after which the cells were also fixed. BrdU is a thymidine analogue that incorporates 
a) b) 
ssDNA (BrdU) 
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into the DNA of cells. Visualization of ssDNA was performed with IF by using an antibody that only 
recognizes BrdU in ssDNA but not in dsDNA 68. Once more, MFI of CENPF was quantified for all the 
cells and a threshold was set, allowing to distinguish cells in S/G2.  Once more, quantification of cells 
with high expression of CENPF revealed no difference between conditions in cells untreated (data not 
shown). Besides, as visualized with pan-nuclear γ-H2AX, only #7-3 didn’t show significant decrease of 
ssDNA, when compared to untransduced (Wt) cells. Yet, this time it appeared sensitive to Olaparib, 
though to lesser extent than the other clones.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 – Clonogenic assay in the presence of 3µM Olaparib at the time of experiments from Fig.10. a) Crystal violet 
staining of untransduced HeLa cells, HeLa cells transduced with shBRCA1 lentivirus particles, and Abraxas and BRIP1 
knockout clones treated with DMSO (vehicle) or Olaparib (3µM) during 12 days, at the time of experiment showed in Fig.10a 
and c) at the time of experiment showed in Fig.10b. b), d) Quantification of cell survival from a) and c), respectively, by 
measurement of absorbance of  crystal violet at 590 nm. Graph shows cell survival ratio between Olaparib and DMSO 
treatment. All values were normalized by the mean of the blank. Mean is shown from three independent measurements. 
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5. Discussion 
 
Over the past 20 years, there has been considerable progress in our understanding of the 
biological functions of BRCA1, which has led to the development of new therapeutic approaches that 
target tumors with loss-of-function mutations in BRCA1. An approach that has been used to treat 
these tumors is to exploit the genetic concept of synthetic lethality. Inhibition of PARP1 has been 
shown to be synthetically lethal with deficiency of BRCA1. This observation provided the impetus for 
PARP1 inhibitors to be tested clinically which has recently resulted in the approval of the first PARP1 
inhibitor, Olaparib, for the treatment of patients with germline mutations in BRCA genes. Although 
this approach has shown promise, multiple potential resistance mechanisms have been identified. In 
order to overcome this problem, a better understanding of BRCA1’s molecular function and its 
binding partners is needed, so better therapeutic approaches can be developed. To achieve this, we 
decided to investigate the roles of the BRCA1-A and -B complexes in DNA repair pathway choice and 
in replication stress. Opposite to the BRCA1-C complex which is known to be involved in DNA end-
resection, the functions of BRCA1-A and BRCA1-B is still are not well understood.  
In order to study the role of BRCA1-A and -B complexes in DNA repair pathway choice and in 
replication stress, we used the CRISPR–Cas9 system to generate Abraxas and BRIP1 knockout clones 
in HeLa cells. As main adaptors of the respective binding complexes, we assume that depletion of 
Abraxas or BRIP1 leads to disruption of their binding complexes. The approach described here, using 
the incorporation of a selection mrker, allowed us to have a higher efficiency. We needed to screen 
only a moderate number of clones in order to find the clones where the target gene was disrupted. 
Besides, insertion of the Blasticidin resistance cassette avoids in frame mutations, which also 
enhances the efficiency of this strategy.    
According to our results, depletion of Abraxas or BRIP1 renders cells sensitive to PARP1 
inhibition, in this case, Olaparib. These results are consistent with the idea that both BRCA1-A and –B 
complexes are involved in HDR. Moreover, our results show that sensitivity of Abraxas knockout 
clones to Olaparib is correlated with an increase of 53BP1 nuclear foci in S/G2 cell phases, upon IR-
induced DNA damage, when compared with the mother cells (Wt), as it is observed in BRCA1-
knocdown cells. This suggests that assembly of the BRCA1-A complex is important for inhibiting 
53BP1 localization at DSBs.  This is consistent with the proposed role of BRCA1-A in targeting BRCA1 
to DSB sites 44,46. Nevertheless, only one of the Abraxas knockout clones, #14-2, showed a significant 
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increase of RIF1 foci formation in S/G2. We suspect that this fact is due to inter-clone heterogeneity. 
Indeed, clone #9-1 is less sensitive to Olaparib than #14-2, which might be explained by the lack of 
increase of RIF1 foci number. RIF1 accumulates at DSB sites in a manner that depends on both 53BP1 
and ATM kinase activity, where ATM acts at a step between 53BP1 and RIF1, through 53BP1 
phosphorylation10,69. Thus, the increase of 53BP1 foci without the increase of RIF1 foci might be 
explain by differences in ATM expression. However, we did not confirm this experimentally. 
Moreover, our results also show that knockdown of 53BP1 or MAD2L2 leads to a decrease of Abraxas 
protein expression of BRIP1 knockout clones and in cells transduced with single sh53BP1/MAD2L2, 
when compared with untransduced (Wt) mother cells or untransduced BRIP1 knockout clones, 
respectively. Because, when 53BP1 or MAD2L2 are silenced, NHEJ can’t proceed, BRCA1 does not 
need to displace 53BP1 from DNA DSBs site. This might explain why Abraxas in underexpressed when 
these proteins are silenced, as it is no longer required for BRCA1 localization at DSBs. Further 
experiments are required in order to understand how Abraxas expression or stability is control in 
these conditions. Inconsistently, cells in which BRCA1 was silenced did not behave equally in both 
experiments, showing decreased Abraxas protein expression only in the second experiment 
(shMAD2L2), whereas Abraxas protein expression levels remained the same as in Wt mother cells in 
the first experiment (sh53BP1). Moreover, co-knockdown of BRCA1 and 53BP1, but not BRCA1 and 
MAD2L2, led to underexpression of Abraxas, when compared with untransduced (Wt) mother cells. 
This is probably due to differences in the roles played in DDR, between 53BP1 and MAD2L2. It should 
also be noticed that CtIP protein expression levels are slightly overexpressed in Abraxas knockout 
clone #9-1, which can also explain why this clone is less sensitive, in comparison with #14-2. Although 
our results show that knockdown of 53BP1 leads to lethality in Olaparib, and does not rescue either 
BRCA1-knockdown cells or #14-2, the Abraxas knockout clone #9-1 was slightly rescued by 53BP1 
knockdown. Nevertheless, these results are inconclusive and the lethality upon transduction with 
sh53BP1, observed in the presence of Olaparib, might be a result of an off-target effect. Oppositely, 
silencing MAD2L2 did rescue BRCA1 knockdown cells and both Abraxas knockout clones. These 
results are consistent with the hypothesis that the BRCA1-A complex functions upstream of end 
resection. However, protein expression analysis of the cells used in these experiment (shMAD2L2), 
reveals that Abraxas knockout clones express Abraxas, though in low levels. This might be due to 
expression of an isoform, as an adaptation mechanism. Alternatively, because HeLa cells are known 
to have complex chromosomic aberrations and to be aneuploid, we speculate HeLa cells might have 
more than only two copies of ABRAXAS gene, and that the depletion of the gene by CRISPR-Cas9 was 
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not effective in all gene copies, which led to residual expression of the gene. In order to confirm 
Abraxas’s role in pathway choice, further experiments are required, such as analysis of BRCA1, RAD51 
and Abraxas foci formation after IR exposure, when 53BP1 or MAD2L2 are silenced, and analysis of 5’ 
end resection to monitor HRR in Abraxas knockout clones. On the other hand, BRIP1 knockout clones 
displayed opposite results to Abraxas knockout clones when 53BP1 and RIF1 foci formation was 
quantified. Only BRIP1 knockout #8-7 showed significant increase of 53BP1 foci formation in S/G2, 
when compared with untransduced (Wt) mother cells. Indeed, clone #7-3 is the less sensitive clone to 
Olaparib. These results are consistent with the previous statement that 53BP1 foci formation in S/G2 
after IR, is correlated with sensitivity to PARP1 inhibition. In spite of this, both BRIP1 knockout clones 
revealed a significant increase in RIF1 foci formation, upon IR-induced DNA damage. Because, as 
referred before, RIF1 accumulation at DSBs is  dependent on 53BP1, it is this difficult to formulate an 
explanation of how RIF1 forms foci without its upstream partner, 53BP1, localizing at DSBs. Different 
functions between 53BP1 and RIF1 in pathway choice might explain this observations. As suggested 
above, these differences between BRIP1 knockout clones can be a result of inter-clone heterogeneity. 
Furthermore, BRIP1 untransduced knockout cells display decreased  Abraxas protein expression, 
when compared to Wt mother cells. The same was not observed in Abraxas knockout clones, where 
BRIP1 expression remained the same as in the Wt mother cells. These results suggest that BRIP1 
expression, or the assembly of the respective complex, might control, directly or indirectly, the 
stability of Abraxas. Further investigation of this mechanism is required to confirm our results.  
Silencing of both 53BP1 or MAD2L2 led to the rescue of the lethality under Olaparib of both BRIP1 
knockout clones, indicating that BRIP1 is also involved in the pathway choice, in steps upstream of 
end resection. Nevertheless, similar to what was mentioned above, analysis of BRCA1, RAD51 and 
BRIP1 foci formation after IR exposure, when 53BP1 or MAD2L2 are silenced, and analysis of 5’ end 
resection to monitor HRR in BRIP1 knockout clones should be performed in order to confirm these 
results. Taking together our results, further experiments should be carried out with the aim of 
understanding if the role in pathway choice of BRCA1-A and –B is cell cycle specific, as BRIP1 has been 
reported to be involved in replication checkpoint control, whereas Abraxas is involved in G2/M 
checkpoint control. 
Replication stalling is at the heart of many chemotherapeutic agents, including the ones that 
block replication fork progression, as PARP inhibitors. BRCA1 has recently been shown to be involved 
in replication stress, where it is involved in stabilization of RAD51 at stalled replication forks to 
protect nascent strands from MRE11-dependent degradation 32–34. Consequently, it was shown that 
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RF protection in BRCA1-deficient cells can lead to resistance to PARP inhibition 31. Hence, we decided 
to investigate if the BRCA1-forming complexes A and B also play a role in the replication stress 
response. Our results show a consistent display of pan-nuclear γ-H2AX upon treatment with fork 
stalling agents, i.e. HU. However, cells transduced with shBRCA1, both Abraxas KO clones and one of 
BRIP1 knockout clones (#8-7) showed a decrease in intensity, compared with untransduced (Wt) 
mother cells. A reduction in pan-nuclear γ-H2AX in cells deficient in BRCA1 or BRIP1 is consistent with 
the idea that BRCA1-B is involved in replication stress response, as its assembly is necessary for ATR-
dependent phosphorylation events, such as the phosphorylation of H2AX. On the other hand, the 
reduction of intensity observed in Abraxas knockout clones might reveal a novel role of BRCA1-A in 
replication stress response. The same pattern was observed when ssDNA was quantified, where cells 
transduced with shBRCA1, both Abraxas KO clones and one of BRIP1 knockout clones (#8-7) showed a 
decrease in ssDNA, compared with untransduced (Wt) mother cells. The results observed in cells 
where BRCA1 is silenced can be explained by the instability caused by the lack of fork protection 
when BRCA1 is absent. Thus, MRE11 is able to access the stalled fork, leading to RF degradation, 
which might explain the decrease of ssDNA. Consequently, the decrease in Abraxas and BRIP1 
knockout might indicate that these complexes are involved in BRCA1’s function in protecting the fork. 
Hence, further experiments should be carried out in order to confirm these results, such as co-
localization of ssDNA with MRE11 and measurement of DNA synthesis using DNA fiber or DNA 
combing assays. 
 
 
 
 
 
 
 
 
 
29 
 
6. Conclusion and Future Perspectives 
 
 Together, our results show that depletion of either Abraxas or BRIP1, and thus, disruption of 
the respective complexes, is synthetically lethal with PARP1 inhibition. We suggest that this 
phenotype is a result of the role played by BRCA1-A and BRCA1-B in HDR, more specifically, in the 
DNA repair pathway choice. Moreover, BRIP1 expression, or the assembly of BRCA1-B, appears to 
influence the expression of Abraxas. Here, we also propose a role in replication stress response 
played by BRCA1-A and –B complexes. However, further investigation is needed to validate our 
findings. 
The gain of insight into BRCA1 complexes is mostly based on experiments that study each 
complex separately. Here we perform a “side-by-side” analysis of both complexes, allowing a more 
trustable analysis by eliminating the variability between studies. Nevertheless, all the experiments 
here shown were performed using the same tumor-derived cell line, HeLa. Thus, it is also necessary 
to verify if these results are reproducible in other cell lines. Additionally, the observed high variability 
between the knockout clones for the same gene, which could be potentially explained by off-targets 
effects. A higher number of sgRNAs per gene could be used to overcome this problem. We also 
suggest  to use a cell line with a well-defined karyotype, where the number of gene copies is known, 
in order to be sure the knockout of the gene is present in homozygoty. To assure this, we suggest the 
use of haploid cells, such as HAP1 cell line. 
In order to better understand the functions of these complexes, a systematic analysis of all 
the components that form each complex is necessary. Furthermore, it is also important to 
understand what is the role of the binding of BRCA1 in these complexes, and if it is essential for the 
functions played by the complexes. Likewise, it still remains unknown if the complexes can regulate 
each other. Finally, it still remains unknown how BRCA1-A and –B act in response to PARP1 inhibition. 
Thus, a full understanding of BRCA1 and its binding partners’ role in DNA repair and replication stress 
can help to understand new ways of resistance to the current drugs used in BRCA-deficient cells, and 
to improve the current therapeutic approaches. 
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